Rationale, aims and objectives Most of the clinical guidelines in low-resource countries are adaptations from preexisting international guidelines. This adaptation can be problematic when those international guidelines are not based on current evidence or original evidencebased international guidelines are not followed. This study aims to evaluate the quality of an Indonesian type 2 diabetes mellitus guideline adapted from selected international guidelines. Results Perkeni's guideline satisfied 55% of the AGREE II items, while its parent guidelines satisfied 59% to 74%. Perkeni's shows low score on "rigor of development" and "applicability" and the lowest score in the "scope and purpose" domain. Differences were found in 4 recommendations: the screening of diabetes, control of hyperglycemia, target blood glucose, and treatment of dyslipidemia. In 3 of 4, Perkeni followed the ADA's recommendation.
of care. However, guidelines developed by various institutions for similar health problems may result in conflicting recommendations. 2 To ensure the quality of the guidelines, transparency on the development process is considered crucial, in particular a rigorous approach to the development is needed, and various skills and experts should be involved. 3, 4 For some institutions, especially those in developing countries, the availability of such resources is often limited. 5, 6 A recent systematic review on diabetes guidelines in non-western countries found that 79% of the guidelines were based on recommendations from other national or international guidelines. 7 Nevertheless, an adaptation of a guideline produced in one cultural and organizational setting for use in another setting (trans-contextual adaptation 8 ) needs to ensure that the resulting and final recommendations could still preserve its validity.
The overall aim of adaptation is to take advantage of existing guidelines to enhance the efficient production and use of high-quality adapted guidelines.
Several approaches to adoption and adaptation of guidelines to local situation have been proposed and endorsed, such as the ADAPTE collaboration 9 and the "Systematic Guidelines Review method." 10 Basically, the approaches should involve systematic search and selection of guidelines, a quality assessment of the guidelines, and a transparent approach during recommendation formulation, plus an external peer review and a formal endorsement procedure. While this approach involves relatively complex processes and certain expertise, these are scarce sources in low-resources countries.
In Indonesia, the adoption and adaptation of international guidelines has also been chosen as a pragmatic and practical approach to guideline development. Currently the number of clinical practice guidelines in Indonesia is less than 20. Although no data are available, observation by the author revealed that all of the guidelines were developed using that approach. One such clinical guideline is the so- Interview with the person responsible for the development of the current Perkeni guideline was conducted by the principal investigator (I.S.) to obtain more insight into the guideline development process.
| Comparison of adopted guideline with its parental guidelines
We identified 6 major clinically relevant recommendations from the Perkeni guideline: (1) the screening of diabetes; (2) the diagnosis of type 2 diabetes mellitus; (3) the control of hyperglycemia; (4) the target blood glucose; (5) the target blood pressure; (6) the treatment of dyslipidemia. I.S. and G.W. extracted the major clinically relevant recommendation from the guidelines.
I.S. and G.W. compared the similarity of each recommendation statement with the 4 parent guidelines. For each major recommendation in Perkeni, we also assessed which parent guidelines was followed (ie, which recommendation has been adopted). In addition, we identified and checked citations of the original research used as the source for each recommendation in the parental guidelines. We identified the highest quality of study design among the references as the representative level of evidence for each recommendation.
3 | RESULTS
| The guidelines
Three of the parent guidelines (IDF, AACE, and ADA) made general recommendations on the medical treatment and early identification of complications and comorbidities of diabetes. Meanwhile, the joint consensus of the ADA and EASD focused on the pharmacologic intervention for hyperglycemia (see Table 1 ).
The recommendations of the ADA, AACE, and ADA-EASD guidelines are based on a combination of expert opinion and literature reviews. IDF guideline is the only guideline that had no explicit reference to expert opinions/consensus or clinical judgment. Table 2 shows the overall wide variation in the fulfillment of the AGREE II items for all of the guidelines. Still, all guidelines attained scores higher than 80% in the "clarity of presentation" domain. Yet in all other domains, the scores varied considerably, and in the "rigor of development" domain, only IDF guideline obtained a score higher than 50% while in the "applicability" domain all guidelines obtained scores lower than 40%. Compared with the other guidelines, Perkeni guideline has the lowest quality in all AGREE II domains except for "scope and purpose."
| Quality of the guidelines
During the interview, the process of developing the guideline by
Perkeni was usually started with 1 small team consisted of 1 or 2 experts supported by 1 or 2 technical team members developing the first draft. Rigorous and systematic searching on the identification of the source guidelines was lacking, while the appraisal of the quality of the original research that was used as the source for each recommendation in the parental guidelines. The draft of the guideline was then presented several times in society meetings to gain consensus.
Meanwhile, the guideline development team searched for evidence to support the agreed recommendations. Table S3 shows the source of the Indonesian guideline recommendations and the highest level of the study design used to build the recommendation in each parent guideline. Recommendations for the management of type 2 diabetes mellitus were rather similar across the parent guidelines, but the detail varied.
| Comparison of the recommendations with PERKENI guideline
Perkeni and all parent guidelines have similar criteria to diagnose diabetes (based on the presence of classic diabetes symptoms and blood glucose or HbA1c measurement) and recommend that blood pressure should be lowered below of 130/80 mm Hg.
Differences between the parent guidelines were found in 4 areas:
screening for diabetes, control of hyperglycemia, blood glucose target, and dyslipidemia management.
| Screening for diabetes
All parent guidelines agreed that the screening of asymptomatic patients for diabetes should be targeted to high-risk adults. Differences existed in defining those at risk especially in terms of age group and nutrition status. In the AACE guideline, an individual aged above 30 years should be screened for any diabetes' risk factors. According to the ADA guideline, age older than 45 years and nutritional status are preconditions for screening while the IDF provides no information.
Perkeni adopted ADA screening recommendation for individuals who are overweight/obese or aged older than 45 years. is not achieved. However, the IDF recommendation did not mention a period for this target.
| Blood glucose target
Perkeni recommends a somewhat lenient blood glucose target of HbA1c < 7 compared to HbA1c < 6.5%. This is an adoption of the ADA and ADA-EASD recommendations.
| Dyslipidemia management
All guidelines recommend statin as a preferable treatment, but for different specific indications. IDF and ADA guidelines recommend statin prescription based on age group (above 40 years) and the presence of CVD or CVD risk factors, regardless of baseline lipid levels.
The AACE recommends taking baseline lipid levels and prescribing statins when needed to achieve certain target lipid levels. Perkeni recommendations were adopted from IDF and ADA guidelines. 
| Citations of different recommendations
The recommendation from ADA and AACE on the importance of screening of high-risk individuals for diabetes was made based on their own independent literature review. Only IDF cited primary studies such as the UKPDS 21 and a population study by Harris et al, 22 in addition to WHO consultation report. 23 However, no further references could be traced from the 3 guidelines on the risk factors which warrant IDF recommendation that pharmacologic intervention should be given when target blood glucose is not achieved by lifestyle modification was adopted from several other guidelines [27] [28] [29] [30] and the UKPDS trial. 31 ADA recommendation on blood glucose target of HbA1c < 7 was made based on several trials including the ACCORD trial, which demonstrated no benefit of intensive glycemic control on CVD outcomes. 32 The source of recommendation on blood glucose target from the latest ADA-EASD was the 2008 version of the ADA guideline. 33 Between the 2 guidelines (AACE and IDF), which have recommended both lower HbA1c target (<6.5), the only common source being used is the prospective observational UKPDS 35 study. 34 While AACE cited several other trials and observational studies in their 2006 Consensus Conference Report 35 for this recommendation, IDF cited systematic review of prospective observational studies by Laakso et al 36 and Selvin et al, 37 together with several guidelines including the 1999 IDF guideline. 38 Both AACE and IDF did not include the Data presented are AGREE II scores (0-100; low scores reflect poor quality). Each item was rated on a 7-point Likert scale that measured the extent to which an item was fulfilled: strongly disagree (1) to strongly agree (7). Scores were standardized within domains by dividing the difference between the consensus score and the minimum possible score by the difference between the maximum and minimum possible scores.
ACCORD trial while the study was published after both guidelines have been released.
Several trials were cited by 3 parent guidelines (AACE, ADA, and IDF) to recommend that statins are the pharmacologic treatment of choice for lipid management of diabetic patients; the commonly cited reference were the Heart Protection Study (HPS) 39 and the Collaborative Atorvastatin Diabetes Study (CARDS). 40 Several other guidelines were also cited by the AACE and IDF on their recommendation on statins.
| DISCUSSION
The quality of the Indonesian diabetes guidelines is poor based on its low AGREE II score, especially in 4 areas: stakeholder involvement, rigour of development, applicability, and editorial independence. Our finding on the low AGREE II scores in each parent guideline, especially in the "Rigor of development" domain, means that generally those parent guidelines failed to show that they have conducted a systematic review on the best available evidences. 41 A previous systematic review that assessed the quality of 24 CPGs on diabetes management reported similar findings. 42 Another study that examines the quality of CPGs that included recommendations on pharmacotherapy for glycemic control in type 2 diabetes mellitus indicated several guidelines that achieve higher score on the "rigor of development area" such as those developed by the UK National Institute for Health and Clinical Excellence, the Scottish Intercollegiate Guidelines Network, and the American College of Physicians. 42 Careful appraisal and selection of the source guidelines is clearly paramount before adapting recommendations from 1 guideline to another. 43 Several studies revealed that there are considerable variations and even conflicting recommendations concerning type 2 diabetes mellitus management from different guidelines. 44, 45 Variation was believed to be due to insufficient evidence, differing interpretations of evidence, unsystematic guideline development methods, the influence of professional bodies, cultural factors such as differing expectations of apparent risks and benefits, socioeconomic factors, or the characteristics of the health care systems. 46 Our study revealed that even though all the source guidelines cited the same studies, yet they can come up with different recommendations. There is a higher chance that the (clinical) judgment of the guideline developer plays a dominant role in the final recommendations.
As expected, each of the guideline used different sources. In the era where evidence-based clinical practice guidelines are reinforced, systematic searching of the evidence is considered a vital process in the guideline development. While sources included for recommendations in Perkeni have been taken from parent guidelines, transparency on and justification of their appropriateness is lacking.
This was also a finding of Aarts et al in their study on Obstructive Sleep Apnea-Hypopnea Syndrome guidelines. 47 Although a wide range of diabetes guidelines existed, the most cited are guidelines from ADA, IDF, EASD, and AACE. 7 This might explain the use of these 4 guidelines by Perkeni. In both ADAPTE collaboration 9 and the "Systematic Guidelines Review method," 10 the systematic search and selection of the guidelines, the quality assessment of the guidelines, and the transparent approach on the formulation of the recommendation are considered crucial steps in the guidelines adaptation process. However, we found no statement in the guideline that shows that this approach has been followed by Perkeni. This was confirmed during the interview with the Perkeni guideline developers.
Engaging potential end users in the process of evaluating and adapting existing guidelines may help improve the uptake and utilization of the guideline. 48 This process has also been overlooked in the Indonesian type 2 diabetes mellitus guideline development; hence,
we found in our previous study that the adherence to the recommendations on the Indonesian type 2 diabetes mellitus guidelines is very low. 49 As far as we know, this is a first study that examines how the recommendations from different guidelines were being adapted to develop a local diabetes guideline. Previous studies compared the quality and recommendations from different diabetes guidelines from different countries or different institutions. 42, 44, 45, [50] [51] [52] While our findings only concern the Perkeni diabetes guideline, they may hold true for other guidelines developed under similar conditions.
In this study, we minimized the observer bias during the assessment of the guideline quality through independent extraction and quality assessment by 2 researchers. While findings reported are mainly based on the literal or statements from the guidelines, we only interviewed the developers of the Perkeni guideline.
Implementing evidence-based practice principles in guideline adaptation will help the efforts in low-resource countries to improve their quality care practice through the use of high-quality practice guidelines. In addition, these countries should aim to improve their capacity in assessing and selecting the guidelines as part of the adaptation process. In the future, the guideline could gain strength and quality by improving transparency in the process of guideline adaptation and by selecting guidelines that fulfill the AGREE II criteria at a high level to be adapted.
| CONCLUSION
In view of the potential impact of CPGs on health care delivery and patient outcomes, it is crucial that clinical guidelines should be of optimal quality. The process underlying the Indonesian type 2 diabetes mellitus guideline development is curtailed because of being underresourced, and the use of the cited suboptimal source guidelines might risk the validity of the recommendations it contains. Implementation of evidence-based practice principles such as those proposed by ADAPTE collaboration should be adhered to when guideline is derived from other guidelines to be used in other than its original context or circumstances.
